Kornimate/medical-research-clean huggingface dataset:
evaluating the efficacy of current treatments for reducing postoperative ileus

Conditions: Post-operative Ileus

Summary: aim was to investigate efficacy of current treatments - water, chewing gum, and olive oil, in resolving postoperative ileus.


Eligibility criteria:
inclusion criteria: * patients underwent abdominal surgery for non neoplastic diseases exclusion criteria: * metastatic disease * history of inflammatory bowel disease * postoperative fever * gastrointestinal fistula * mint or olive allergy; and/or * earlier abdominal radiation
a study to evaluate the efficacy and safety of recombinant human growth hormone injection in patients with prader-willi syndrome

Conditions: Prader-Willi Syndrome

Summary: to evaluate the effectiveness of rhgh (recombinant human growth hormone) injection for improving motor development in patients with pws.


Eligibility criteria:
inclusion criteria: * 1.signed informed consent from legal guardian of the subjects; * subjects are willing and able to cooperate to complete scheduled visits, treatment plans and laboratory tests and other procedures; * diagnosed as pws by gene test; * age: 1 month (30 days after birth) - 5 years of age; * male or female; * calculated by peabody developmental motor scale, total motor quotient, gross motor quotient or fine motor quotient is less than 90 points; * thyroid function is within the normal reference range or remained within the normal reference range by substitution therapy; * no history of rhgh therapy before. exclusion criteria: * subjects with abnormal liver or kidney function; * subjects with obvious central sleep apnea and/or moderate or severe obstructive sleep apnea, acute lung infection; * subjects with chronic diseases that have long-term effects on bone metabolism and body composition; * subjects with congenital skeletal dysplasia, or spine scoliosis with moderate and above degree requiring treatment or lameness; * subjects with history of congenital heart disease, or an echocardiogram showing that the structural abnormalities require surgery or interventional therapy or that the left ventricular ejection fraction is \<40%, or the abnormal electrocardiogram requiring intervention; * subjects with history of convulsions or epilepsy; * subjects with other systemic chronic diseases; * subjects with diagnosed tumors; * subjects with family history of cancers, a previous history of cancer, or considered to be a high risk of cancer combinating other information; * subjects with mental disease; * subjects with diabetes, or abnormal fasting glucose and researchers believe that may affect the safety of the subject; * subjects with severe obesity; * subjects with highly allergic constitution or allergy to proteins or investigational product or its excipient; * subjects who took part in other clinical trials within 3 months ; * subjects who received drug treatment that may interfere with gh secretion or gh action within 3 months; * other conditions in which the investigator preclude enrollment into the study
day case laparoscopic cholecystectomy: fundus first with ultrasonic dissection or conventional diathermy hook

Conditions: Cholecystolithiasis

Summary: day case laparoscopic cholecystectomy can be made with conventional diathermy hook starting at triangle of calot´s. ultrasonic dissection starting from the gallbladder fundus is another option. the aim is to test the hypothesis that with ultrasonic dissection technique a better same day discharge and a shorter operative time can be achieved.

after initiation of general anesthesia patients are randomized either to conventional or ultrasonic dissection group. the patients and recovery room personnel are blinded to the operative technique used.

Eligibility criteria:
inclusion criteria: * asa i-ii * bmi under 35 * normal liver enzymes * no bile duct dilatation in ultrasound * cholecystolithiasis exclusion criteria: * nsaid allergy * previous upper gi-surgery * common bile duct stones in preoperative imaging * history of severe acute pancreatitis

Keywords: laparoscopic cholecystectomy
the evaluation and treatment of elevated left-sided filling pressures by balloon inflation within the ivc

Conditions: Hypertension, Pulmonary; Heart Failure

Summary: in patients with heart failure, elevated filling pressures may contribute to symptoms while not improving cardiac output. the current study is focused on evaluating the relationship between exercise capacity, pulmonary pressures, cardiopulmonary parameters, and symptoms of dyspnea in patients with heart failure during exercise.

previous studies have suggested that intracardiac pressures can be decreased without compromising cardiac function. during an invasive cardiopulmonary exercise test (cpet), catheters are placed within the heart and pulmonary vasculature to evaluate cardiopulmonary function in response to exercise. we will be testing whether pulmonary hypertension can be prevented during exercise by adjusting right ventricular pre-load. we will also be evaluating parameters of cardiopulmonary function during the study.

Eligibility criteria:
inclusion criteria: 1. subjects scheduled to undergo an exercise right heart catheterization at el camino hospital. 2. new york heart association (nyha) ii or iii. 3. subjects must be between 18 and 80 years of age. 4. a left ventricular ejection fraction ≥ 35%. 5. subjective or objective evidence (e.g. 6 minute walk test) of impaired exercise capacity. 6. is willing and able to sign an irb-approved written informed consent exclusion criteria: 1. inability to peddle exercise while laying flat. 2. more than mild valve disease. 3. clinical or objective evidence of inducible myocardial ischemia. 4. significant lung disease, such as prior diagnosis of copd. 5. resting or dynamic outflow tract gradient. 6. severe pulmonary htn (\>60mmhg at rest) 7. moderate to severe rv dysfunction 8. history of dvt, pe 9. pregnancy (women of child-bearing age, regardless of contraceptive measures, must be willing to take a pregnancy test prior to the study). 10. recent major surgery or hospitalization (within 30 days) 11. participation in another clinical study (within 30 days) 12. advanced neurological disease (e.g. dementia)
optimizing parameters of low-intensity focused ultrasound for cortical modulation in stroke patients

Conditions: Stroke

Summary: the purpose of this research study is to find out the optimal intensity and frequency of low intensity focused ultrasound (lifu) that is safe and tolerable in people who have had a stroke.

aim 1 is to determine the optimal intensity of low intensity focused ultrasound stimulation (lifus) in stroke patients in terms of safety. we will investigate the optimal spatial-peak temporal-average intensity/ispta in the range of 0(or sham) w/cm2 to 8 w/cm2. safety will be investigated by assessing clinically detectable signs and symptoms by monitoring vital signs and surveying subjects with a questionnaire before and after each stimulation session, and additionally by detecting subclinical neuronal injury using mri/dwi. aim 1 requires up to 36 subjects. aim 2 is to determine the optimal frequency of lifu stimulation in stroke patients in terms of cortical excitability. stroke subjects undergo each of the 5 frequency levels (0.35 mhz; 0.5 mhz; 0.75 mhz, 1.0 mhz and 1.5 mhz) on 5 different days with at least one day washout. the intensity (ispta) will set up at the level that is determined from aim 1. cortical excitability is measured by the amplitude of motor evoked potentials (meps) induced by transcranial magnetic stimulation (tms) from the abductor pollicis brevis (abp) muscle of the affected side. meps will be recorded pre- and post-stimulation to determine the optimal intensity for maximal cortical excitability from the hemisphere where the lesion is located. aim 2 requires 18 subjects.

Eligibility criteria:
inclusion criteria: 1. ≥ 21 years old of any gender and race; 2. clinical ischemic stroke or hemorrhagic (confirmed by ct or mri) that occurred \>= 2 months ago 3. predominantly unilateral motor impairment with fm-ue score ≤ 62/66; 4. meps are inducible from a hand muscle on the affected side (i.e. abductor pollicis brevis (apb) muscle). exclusion criteria: 1. any concomitant neurological disorder affecting arm function; 2. documented history of severe dementia with or without medication before stroke; 3. subject is unable to do the motor learning practice at the baseline; 4. presence of any mri/tms/ultrasonic stimulation risk factors: an electrically, magnetically, or mechanically activated metal or nonmetal implant including cardiac pacemaker, intracerebral vascular clips, or any other electrically sensitive support system; non-fixed metal in any part of the body; pregnancy (the effect of tms/ultrasonic stimulation on the fetus is unknown); no history of seizure before or after the stroke; preexisting scalp lesion or wound or bone defect or hemicraniectomy.

Keywords: low intensity focused ultrasound stroke brain stimulation ultrasonic stimulation
low dose of cannabidiol (cbd) to treat mild to moderate musculoskeletal pain

Conditions: Musculoskeletal Pain

Summary: the purpose of the study is to evaluate whether pure green tablets is a better pain reliever for the treatment of mild to moderate musculoskeletal pain.


Eligibility criteria:
inclusion criteria: 1. male or female at least 21 years of age; 2. subject has mild to moderate musculoskeletal pain; 3. pain for greater than or equal to 10 days of each month for 3 months prior to study entry for which the pain requires treatment. 4. has an numeric pain rating scale (nprs) score of 3 or greater, 5. if female, subject is practicing an approved method of birth control throughout the study; 6. subject is willing and able to comply with all protocol-specified requirements; 7. subject is willing to take pure green tablets only and will not take any other pain medications, 8. subject is willing to provide his/her written informed consent to participate in the study as stated in the informed consent document. 9. subject is willing to document pain scale scores in a diary. exclusion criteria: 1. subject has any condition for which the investigator does not feel the participant should be enrolled due to possible safety or compliance issues; 2. subject has received treatment with an investigational drug or therapy within 30 days or 5 half-lives (whichever is longer) prior to day 1. 3. subject has a known allergy to active or inert ingredients of pure green tablets; 4. subject is taking a concomitant medication or treatment that would complicate use or interpretation of the study drug's effects (examples include: cannabis (marijuana) or any cannabinoid products including cannabidiol (cbd) or tetrahydrocannabinol (thc); any drug or herbal product that influences the endocannabinoid system (ecs)); 5. have serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study. 6. have a history of recurrent seizures other than febrile seizures. 7. have current or pending disability compensation or litigation issues that may compromise response to treatment, in the opinion of the investigator. 8. have a diagnosis of inflammatory arthritis (that is, rheumatoid arthritis) or an autoimmune disorder (excluding inactive hashimoto's thyroiditis). 9. use of acupuncture, chiropractic maneuvers, transcutaneous electrical nerve stimulation (tens), or similar procedures aimed to relieve any kind of pain. 10. patients who are anticipated by the investigator to require use of analgesic agents including but not limited to non-steroidal anti-inflammatory drugs (nsaids), acetaminophen/paracetamol, and opioids, or other excluded medication for the duration of the study. 11. are unwilling or unable to comply with the data collection method used to record their patient rated outcome data.

Keywords: cbd cannabidiol musculoskeletal pain pain
covid-19 immunity assessment

Conditions: COVID-19

Summary: the purpose of this study is to collect blood specimens from individuals post infection or post vaccination over time to assess covid19 immunity.

the dxterity covid-19 immunity assessment collection mailer kit contains the dxcollect microcollection device (mcd) serology fingerstick blood collection device packaged as a home collection kit, designed for collection and shipment of fingerstick blood back to dxterity clia (clinical laboratory improvements amendment) certified laboratory for testing. the clinical performance of the collection device for use with anti-sars-cov-2 antibody tests will be evaluated for use with cpass™ anti-sars-cov-2 neutralizing antibody detection kit (eua 201427). the samples may also be used for assessing immunity or protection post covid-19 vaccination.

Eligibility criteria:
inclusion criteria: * males and females ≥13 years old. * not vaccinated and were previously positive for covid-19 or are vaccinated for covid-19. * provides test report to demonstrate prior covid-19 positive result (only applicable to unvaccinated subjects who were previously positive for covid-19, not applicable for covid-19 vaccinated subjects). * provides informed consent and completed questionnaire. * able to register the collection kit on the dxterity portal. * able to collect and ship blood samples back to dxterity. exclusion criteria: * unable to provide covid-19 positive test report (only applicable to unvaccinated subjects who were previously positive for covid-19, not applicable for covid-19 vaccinated subjects). * unable to complete informed consent and/or questionnaire. * unable to complete the study activities in a timely manner.
longterm follow-up after remote ischemic preconditioning for prevention of contrast-induced nephropathy

Conditions: Impaired Renal Function

Summary: remote ischemic preconditioning reduces the incidence of contrast-induced acute kidney injury in patients undergoing elective coronary angiography. this study was designed to acquire long-term data of initially randomized patients in the renpro trial.

data of the renpro trial has been already published. in the present study data of longterm follow up are collected.

Eligibility criteria:
all patients who participated to the renpro trial

Keywords: preconditioning contrast-induced acute kidney injury renal faliure
curosurf® in adult acute respiratory distress syndrome due to covid-19

Conditions: COVID-19; ARDS, Human

Summary: surfactant replacement therapy (srt) improves oxygenation and survival in nrds and some infant ards. srt was tried in adult ards with conflicting results. research by filoche and grotberg helped to understand the failure of previous clinical trials and yielded a strong scientific rationale for srt success, now allowing to design a new administration protocol for srt in adults, to be tested by this clinical trial in covid-19 adult ards patients. patients will be randomized to receive either a bronchial fibroscopy alone (with aspiration of secretions) or a bronchial fibroscopy with administration of 3 ml/kg of a solution of poractant alpha diluted to 16 mg/ml and distributed into each of the 5 lobar bronchi.


Eligibility criteria:
inclusion criteria: * at least 18 years * intensive care unit admission. * intubation and mechanical ventilation since less than 72h. * positive end-expiratory pressure ≥ 5 cmh2o. * acute respiratory distress syndrome following berlin definition. * covid-19 * pao2/fio2 ratio \< 150 mmhg during at least 3 hours despite pep trial. * compliance of the respiratory system \< 50 ml/cmh2o exclusion criteria: * contraindication to prone position. * pregnancy. * weight \< 40 kg * height \ 190 cm. * profuse bronchorrhea (at least 1 succion per hour during 3 hours). * other significant cause than ards to the respiratory failure. * decision to limit active therapies. * no arterial line in place. * obesity with weight / height ratio \> 1 kg / cm. * impossible to give neuromuscular blockers (e.g. drug unavailable owing to global pandemia). * severe chronic respiratory failure with oxygen at home. * other severe acute or chronic organ faillure (eg severe liver cirrhosis, severe chronic cardiac failure). * history of pneumonectomy or pulmonary lobectomy. * patient scheduled for extracorporeal membrane oxygenation. * known hypersensibility to curosurf. * contraindication to bronchial fibroscopy. * person under legal protection.
postoperative pain control using local wound infiltration in adolescent idiopathic surgery

Conditions: Postoperative Pain; Spinal Fusion

Summary: non-opioid methods of pain management following posterior spinal fusion (psf) have become increasingly popular given the rise of opioid abuse and opioid-related deaths. orthopedic surgery remains one of the highest prescribing subspecialties. local wound infiltration is an effective method of acute pain management following surgical intervention and is the standard in some surgical subspecialties, however, no randomized control trials (rct) exist in the pediatric spine literature. this would be the first (rct) to assess the use of local would infiltration in postoperative pain control following psf for adolescent idiopathic scoliosis patients (ais). the primary aim of this study is to investigate the efficacy of local wound infiltration with anesthetic agents in reduction of postoperative pain scores and post-operative opioid use during hospital admission following fusion surgery in ais patients. the proposed single-center, double-blind prospective randomized study will be conducted by recruiting patients meeting the inclusion criteria of age 10-26 years and diagnosis of ais undergoing posterior fusion surgery. study participants will be randomized into either a local injection of 0.25% bupivacaine with epinephrine or a placebo of equal volume injectable saline. patient-reported outcomes will be collected at 1-, 6-, 12- and 24-months postoperatively.


Eligibility criteria:
inclusion criteria: * ≥10 years old and ≤17 years old at assessment * diagnosis of adolescent idiopathic scoliosis (ais) * planned surgical treatment of progressive spinal deformity with posterior spinal fusion exclusion criteria: * diagnosis of neuromuscular, syndromic, or congenital scoliosis * history of known allergy to local anesthesia * chronic pre-operative opioid consumptions * any other analgesic treatment for chronic pain before surgery * psychiatric or neurological disorders * cannot fluently read or speak english
effect of zhuli capsule on phlegm-heat syndrome (tan-re zheng)

Conditions: Chronic Obstructive Pulmonary Disease; Chronic Bronchitis

Summary: this trial aims to evaluate the clinical control rate of sputum by zhuli capsule in the treatment of the phlegm-heat syndrome （tan-re zheng）in the patients with acute exacerbation of chronic obstructive pulmonary disease or chronic bronchitis.


Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria of acute exacerbation in chronic obstructive pulmonary disease or chronic bronchitis; 2. meet the diagnostic criteria of phlegm-heat syndrome (tan-re zheng) in tcm 3. age from 18 to 75 years old, regardless of gender; 4. the score of each dimension of the sputum assement scale is ≥1; 5. those who have not participated in other drug clinical research in the past one month; 6. sign the informed consent letter. exclusion criteria: 1. patients with pulmonary tuberculosis, bronchial cancer or other lung diseases. 2. loose stools due to spleen deficiency and stomachache caused by cold. 3. diabetes or severe cardiovascular, liver (alt\>1.5×uln), kidney (cr\>1.5×uln) and other primary diseases. 4. pregnant and lactating women. 5. patients with acute and chronic respiratory failure. 6. those who cannot give full informed consent due to mental disorders. 7. people with disabilities recognized by law. 8. people with allergies, or allergic to the ingredients of the drug used in this test. 9. those who have used drugs with expectorant effects within the day. 10. patients who are participating in clinical trials of other drugs. -
highcycle study: effect of acetazolamide on sleep disordered breathing in women compared to men

Conditions: Sleep-Disordered Breathing

Summary: randomized clinical trial evaluating the effect of acetazolamide on sleep disordered breathing in women compared to men travelling to 3600 m.


Eligibility criteria:
inclusion criteria: * healthy, non-smoking men and women, age 18-44 years, without any diseases and need of regular medication (including oral contraceptives). * bmi \>18 kg/m2 and \<30 kg/m2 * born, raised and currently living at altitudes \<1000 m * written informed consent * premenopausal women with an eumenorrheic cycle exclusion criteria: * other types of contraceptvies (hormonal intrauterine device, vaginal ring, subcutaneous injections or implants, among others) * pregnancy or nursing * anaemic (haemoglobin concentration \<10g/dl) * any altitude trip \<4 weks before the study * allergy to acetazolamide and other sulfonamides

Keywords: sleep disordered breathing periodic breathing prevention acetazolamide altitude hypoxia women
added value of speckle tracking in the evaluation of patients with sickle cell disease

Conditions: Sickle Cell Disease

Summary: sickle cell disease is a serious disease that is life-threatening for patients being homozygous for the ss form or heterozygous for the sc or βthal forms. the chu brugmann hospital currently regularly treats about 70 homozygous adult patients and this number is in constant augmentation. sickle cell disease patients may develop a cardiomyopathy due to chronic anemia, the haemosiderosis risk or, less frequently, to coronary vaso-occlusive damages. the hypervolemia in patients with sickle cell disease causes an overestimation of the ejected left ventricular fraction measured by echocardiography, this parameter being very dependent of the blood volume.it has already been shown that the left ventricular ejection fraction was normal in most patients with sickle cell disease, but that its evaluation by parameters independent from the blood volume showed the existence of a dysfunction. myocardial strain, as measured by speckle tracking, is a echographic evaluation method of the cardiac function, independent of the blood volume. this technique hasn't been used much in sickle cell disease patients. a study using 3d speckle tracking on a limited number of sickle cell disease patients failed to show a strain anomaly. moreover, the study highlighted a higher global longitudinal strain in this patient population. the investigators find these data hard to explain and in contradiction with previous studies using other cardiac function evaluation techniques, independent from the blood volume. the primary goal of this study is thus * to study the longitudinal strain by 2d echography * to determine if anomalies of the longitudinal strain exist in sickle cell disease patients with a normal ejected left ventricular fraction, compared to a control group of healthy patients. the secondary goal of this study is to correlate, inside the sickle cell disease group, the possible strain anomalies with biological gravity parameters of the disease.


Eligibility criteria:
inclusion criteria: * all sickle cell disease patients exclusion criteria: * insufficient echogenicity

Keywords: sickle cell disease echocardiography speckle tracking